BIOGEN INC. — Director's Dealing 2024

Feb 9, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2024-02-07

Reporting Person: Murphy Nicole (Head of Pharm Ops and Tech)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-08	Common Stock	M	2101	—	Acquired	7894.9895	Direct
2024-02-08	Common Stock	F	638	$240.30	Disposed	7256.9895	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-07	Restricted Stock Unit	$0	A	5820	Acquired	2027-02-07	Common Stock (5820)	Direct
2024-02-08	Restricted Stock Unit	$0	M	2101	Disposed	2026-02-08	Common Stock (2101)	Direct

Footnotes

F1: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.

F2: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023.